Fate Therapeutics

Fate Therapeutics Inc. is a clinical-stage biopharmaceutical company based in San Diego, California. The company focuses on developing programmed cellular immunotherapies for cancer and autoimmune diseases. Utilizing a proprietary human-induced pluripotent stem cell (iPSC) platform, Fate Therapeutics creates innovative cell therapies designed to treat various hematological malignancies and advanced solid tumors. The company specializes in off-the-shelf, iPSC-derived cellular immunotherapies, including engineered Natural Killer (NK) cells and T-cell product candidates. These therapies are designed to effectively target cancer cells and elicit specific immune responses. Fate Therapeutics emphasizes the use of clonal master iPSC lines, which provide a renewable source for manufacturing high-quality cell therapy products that can be delivered to multiple patients. The company's mission is to bring first-in-class iPSC-derived cellular immunotherapies to patients, ensuring consistent and accessible treatments.